Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Decentralized Testing for Diagnosis of COVID-19

By LabMedica International staff writers
Posted on 15 Dec 2020
A novel "nanoPCR" technique enables diagnosis of COVID-19 infections in less than 20 minutes with the accuracy of the current PCR method.

The diagnosis of COVID-19 by quantitative PCR with reverse transcription (RT–qPCR) typically involves bulky instrumentation in centralized laboratories and an assay time of one to two hours. The logistics process of cold chain transportation from the sampling sites to the testing facility slows conventional RT-PCR diagnosis even more, often taking one to two days to yield results.

To improve this situation and provide a platform for decentralized testing of suspected COVID-19 patients, investigators at the Institute for Basic Science (Seoul, South Korea) and colleagues in Korea and the United States developed “nanoPCR”, a fast one-pot PCR with reverse transcription (RT–PCR) technology.

The nanoPCR system seamlessly integrated plasmonic thermocycling with fluorescent signal detection in a single device. A key concept was the use of dual-functional magneto-plasmonic nanoparticles (MPNs) for PCR applications. The investigators noticed that most of the plasmonic effect was confined near the surface of plasmonic nanoparticles. By encasing a magnetic core with a plasmonic gold (Au) shell, they achieved: (1) efficient plasmonic heating comparable to that by solid Au nanoparticles; and (2) rapid nanoparticle separation with external magnetic fields to perform in situ signal detection. Exploiting these advantages, they produced a compact nanoPCR system that automatically executed reverse transcription, rapid PCR amplification, and fluorescence detection with a single button press.

The nanoPCR prototype concurrently measured three samples within 17 minutes. The limit of detection was 3.2 gene copies per microliter, which is comparable to that obtained by benchtop PCR equipment.

The investigators used the nanoPCR method to evaluate clinical samples from 75 COVID-19 patients and 75 controls). The nanoPCR device rapidly detected three gene targets (N1, N2 and RPP30) and achieved diagnostic accuracy greater than 99%. There were no false-negative or false-positive results.

Senior author Dr. Cheon Jinwoo, director of the center for nanomedicine at the Institute for Basic Science, said, "Through the improvement and miniaturization of the PCR technology, we have shown that it is possible to perform PCR based POC (point-of-care) diagnosis in the field quickly."

The nanoPCR method was described in the December 3, 2020, online edition of the journal Nature Biomedical Engineering.

Related Links:
Institute for Basic Science


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.